Comment on 'Anti-tumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer'.
作者信息
Shamash J, Sarker S-J
机构信息
St Bartholomew's Hospital, 7th Floor, Gloucester House, Little Britain, UK.
Centre for Experimental Cancer Medicine, Queen Mary University of London, London, UK.
出版信息
Br J Cancer. 2014 Jan 7;110(1):266-7. doi: 10.1038/bjc.2013.736. Epub 2013 Dec 3.
Abstract
摘要
相似文献
1
Comment on 'Anti-tumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer'.关于“阿比特龙与己烯雌酚序贯给药治疗去势抵抗性前列腺癌男性患者的抗肿瘤活性”的评论
Br J Cancer. 2014 Jan 7;110(1):266-7. doi: 10.1038/bjc.2013.736. Epub 2013 Dec 3.
2
Reply: 'Comment on Anti-tumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer'.回复：“关于阿比特龙和己烯雌酚序贯给药治疗去势抵抗性前列腺癌男性患者时的抗肿瘤活性的评论”
Br J Cancer. 2014 Jan 7;110(1):267-8. doi: 10.1038/bjc.2013.737. Epub 2013 Dec 3.
3
Antitumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer.阿比特龙和己烯雌酚序贯给药治疗去势抵抗性前列腺癌的抗肿瘤活性。
Br J Cancer. 2013 Sep 3;109(5):1079-84. doi: 10.1038/bjc.2013.446. Epub 2013 Aug 8.
4
Combination therapy: Abiraterone prolongs survival in metastatic prostate cancer.联合治疗：阿比特龙可延长转移性前列腺癌患者的生存时间。
Nat Rev Clin Oncol. 2011 Aug 2;8(9):515-6. doi: 10.1038/nrclinonc.2011.111.
5
Abiraterone and increased survival in metastatic prostate cancer.阿比特龙与转移性前列腺癌患者生存率的提高
N Engl J Med. 2011 Aug 25;365(8):766; author reply 767-8. doi: 10.1056/NEJMc1107198.
6
Abiraterone acetate is well tolerated without concomitant use of corticosteroids.醋酸阿比特龙在不联合使用皮质类固醇的情况下耐受性良好。
J Clin Oncol. 2010 Oct 10;28(29):e560-1; author reply e562. doi: 10.1200/JCO.2010.29.5170. Epub 2010 Aug 30.
7
Expanding treatment options for metastatic prostate cancer.扩大转移性前列腺癌的治疗选择。
N Engl J Med. 2011 May 26;364(21):2055-8. doi: 10.1056/NEJMe1102758.
8
Abiraterone and increased survival in metastatic prostate cancer.阿比特龙与转移性前列腺癌患者的生存获益
N Engl J Med. 2011 May 26;364(21):1995-2005. doi: 10.1056/NEJMoa1014618.
9
Abiraterone acetate (Zytiga) for metastatic castration-resistant prostate cancer.醋酸阿比特龙（泽珂）用于转移性去势抵抗性前列腺癌。
Med Lett Drugs Ther. 2011 Aug 25;53(1370):63-4.
10
Diethylstilboestrol for the treatment of prostate cancer: past, present and future.己烯雌酚用于前列腺癌治疗：过去、现在与未来
Scand J Urol. 2014 Feb;48(1):4-14. doi: 10.3109/21681805.2013.861508. Epub 2013 Nov 21.
本文引用的文献
1
Antitumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer.阿比特龙和己烯雌酚序贯给药治疗去势抵抗性前列腺癌的抗肿瘤活性。
Br J Cancer. 2013 Sep 3;109(5):1079-84. doi: 10.1038/bjc.2013.446. Epub 2013 Aug 8.
2
Abiraterone in metastatic prostate cancer without previous chemotherapy.阿比特龙治疗既往未接受化疗的转移性前列腺癌。
N Engl J Med. 2013 Jan 10;368(2):138-48. doi: 10.1056/NEJMoa1209096. Epub 2012 Dec 10.
3
A multi-centre randomised phase III trial of Dexamethasone vs Dexamethasone and diethylstilbestrol in castration-resistant prostate cancer: immediate vs deferred Diethylstilbestrol.多中心随机对照 III 期临床试验：地塞米松与地塞米松和己烯雌酚在去势抵抗性前列腺癌中的应用：己烯雌酚的即刻与延迟应用。
Br J Cancer. 2011 Feb 15;104(4):620-8. doi: 10.1038/bjc.2011.7. Epub 2011 Feb 1.
4
A phase II study investigating the re-induction of endocrine sensitivity following chemotherapy in androgen-independent prostate cancer.一项关于在雄激素非依赖性前列腺癌化疗后重新诱导内分泌敏感性的II期研究。
Br J Cancer. 2008 Jan 15;98(1):22-4. doi: 10.1038/sj.bjc.6604051. Epub 2008 Jan 8.
Zotero 插件